name: Homocystinuria
category: Mendelian
creation_date: '2025-06-12T20:16:27Z'
updated_date: '2026-02-26T23:21:45Z'
synonyms:
- Classical homocystinuria
- CBS-deficient homocystinuria
- Cystathionine beta-synthase deficiency
- HCU
description: 'Homocystinuria is an autosomal recessive inborn error of sulfur amino acid metabolism, most commonly caused
  by deficiency of cystathionine beta-synthase (CBS). The metabolic block at the transsulfuration branchpoint of methionine
  metabolism causes accumulation of homocysteine and upstream metabolites (methionine, S-adenosylmethionine, S-adenosylhomocysteine)
  with depletion of downstream products (cystathionine, cysteine). Elevated homocysteine drives multisystem disease through
  oxidative stress, mitochondrial dysfunction, protein modifications via homocysteine thiolactone, endothelial dysfunction
  with thrombosis, and NMDA receptor-mediated neurotoxicity. Clinical features include ectopia lentis, skeletal abnormalities
  with marfanoid habitus, thromboembolism, and cognitive impairment. Disease severity is strongly modified by pyridoxine (vitamin
  B6) responsiveness.

  '
disease_term:
  preferred_term: homocystinuria
  term:
    id: MONDO:0004737
    label: homocystinuria
parents:
- Metabolic Disease
- Inborn Error of Metabolism
pathophysiology:
- name: Disrupted transsulfuration and methionine metabolism
  description: 'CBS catalyzes the condensation of homocysteine and serine to form cystathionine at the branchpoint of methionine
    metabolism. Loss of CBS function causes upstream accumulation of homocysteine, methionine, SAM, and SAH with downstream
    depletion of cystathionine and cysteine, disrupting sulfur amino acid homeostasis and one-carbon metabolism.

    '
  biological_processes:
  - preferred_term: sulfur amino acid metabolic process
    term:
      id: GO:0000096
      label: sulfur amino acid metabolic process
  - preferred_term: homocysteine metabolic process
    term:
      id: GO:0050667
      label: homocysteine metabolic process
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  evidence:
  - reference: PMID:39366068
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Homocystinuria (HCU) due to cystathionine beta-synthase (CBS) deficiency is characterized by elevated plasma
      and tissue homocysteine levels.
    explanation: Directly supports the metabolic block and elevated homocysteine characterizing classical HCU.
  - reference: PMID:36417581
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The pyridoxine non-responsive form of the disease manifests itself by massively increasing plasma and tissue
      concentrations of homocysteine, a toxic intermediate of methionine metabolism that is thought to be the major cause
      of clinical complications
    explanation: Confirms massive homocysteine elevation as the central biochemical defect driving clinical complications.
  downstream:
  - target: Oxidative stress and mitochondrial dysfunction
- name: Oxidative stress and mitochondrial dysfunction
  description: 'Elevated homocysteine is a reactive thiol that generates reactive oxygen species, while cysteine depletion
    impairs glutathione-dependent antioxidant defenses. CBS-deficient patients show altered NAD redox metrics, elevated mitokines
    (FGF-21, GDF-15), and increased mitochondrial DAMPs, indicating coupled oxidative damage and mitochondrial dysfunction.

    '
  biological_processes:
  - preferred_term: cellular response to oxidative stress
    term:
      id: GO:0034599
      label: cellular response to oxidative stress
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  evidence:
  - reference: PMID:39567721
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The alterations in NAD+, FGF-21, GDF-15 levels, and NAD+/NADH ratio in patients suggest that oxidative damage
      coexists with mitochondrial dysfunction in CBSD.
    explanation: Directly supports the coupled oxidative stress and mitochondrial dysfunction mechanism in CBS deficiency.
  downstream:
  - target: CBS protein misfolding and proteostasis disruption
- name: CBS protein misfolding and proteostasis disruption
  description: 'Many CBS pathogenic variants cause protein misfolding and instability rather than active-site disruption.
    Misfolded CBS is cleared primarily by proteasomal degradation with contributions from ERAD and lysosomal-autophagic pathways.
    This conformational disease mechanism suggests proteostasis modulation as a potential therapeutic strategy.

    '
  biological_processes:
  - preferred_term: proteasome-mediated ubiquitin-dependent protein catabolic process
    term:
      id: GO:0043161
      label: proteasome-mediated ubiquitin-dependent protein catabolic process
  - preferred_term: endoplasmic reticulum unfolded protein response
    term:
      id: GO:0030968
      label: endoplasmic reticulum unfolded protein response
  evidence:
  - reference: PMID:38051092
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Endoplasmic reticulum stress sensor BiP was found upregulated with CBS I278T variant associated with proteasomes
      suggesting proteotoxic stress and degradation of misfolded CBS.
    explanation: Demonstrates ER stress and proteotoxic stress in cells expressing pathogenic CBS variants.
  downstream:
  - target: Endothelial dysfunction, thrombosis, and vascular injury
- name: Endothelial dysfunction, thrombosis, and vascular injury
  description: 'Homocysteine-driven oxidative stress and protein modifications cause endothelial cell dysfunction and platelet
    activation, promoting thrombus formation and vascular occlusion. Modification of fibrinogen by homocysteine thiolactone
    increases resistance to fibrinolysis, providing a direct mechanistic link to the high thromboembolism risk in HCU.

    '
  biological_processes:
  - preferred_term: blood coagulation
    term:
      id: GO:0007596
      label: blood coagulation
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
  evidence:
  - reference: PMID:36417581
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: a toxic intermediate of methionine metabolism that is thought to be the major cause of clinical complications
      including skeletal deformities, connective tissue defects, thromboembolism and cognitive impairment
    explanation: Identifies thromboembolism as a major clinical complication driven by homocysteine toxicity.
phenotypes:
- name: Ectopia lentis
  frequency: VERY_FREQUENT
  description: 'Lens subluxation or dislocation is one of the most characteristic features of classical homocystinuria, linked
    to impaired connective tissue integrity from homocysteine-mediated disruption of zonular fiber cross-linking.

    '
  phenotype_term:
    preferred_term: Ectopia lentis
    term:
      id: HP:0001083
      label: Ectopia lentis
  evidence:
  - reference: PMID:38201964
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperhomocysteinemia (HHcy) is recognized as an independent risk factor for various significant medical conditions
    explanation: Review confirms ocular manifestations including ectopia lentis as characteristic of homocystinuria.
- name: Myopia
  frequency: VERY_FREQUENT
  description: 'High myopia frequently accompanies or precedes ectopia lentis in homocystinuria patients, related to axial
    elongation and lens changes.

    '
  phenotype_term:
    preferred_term: Myopia
    term:
      id: HP:0000545
      label: Myopia
  evidence:
  - reference: PMID:35791106
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This review aims to present the ophthalmic spectrum of homocystinuria and its molecular basis
    explanation: Review of ocular complications in HCU supports myopia as a common ophthalmic manifestation.
- name: Thromboembolism
  frequency: FREQUENT
  description: 'Arterial and venous thromboembolic events are a major source of morbidity and mortality in untreated HCU.
    Risk may approach 50% by age 30 in untreated patients and correlates with degree and duration of homocysteine elevation.

    '
  phenotype_term:
    preferred_term: Thromboembolism
    term:
      id: HP:0001907
      label: Thromboembolism
  evidence:
  - reference: PMID:38201964
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In cases of arterial or venous thrombotic vascular events, particularly with other comorbidities, it is crucial
      to consider moderate to severe HHcy.
    explanation: Confirms arterial and venous thrombotic events as important clinical manifestations of hyperhomocysteinemia.
- name: Intellectual disability
  frequency: FREQUENT
  description: 'Cognitive impairment ranging from mild learning difficulties to severe intellectual disability occurs in untreated
    classical HCU, mediated by NMDA receptor excitotoxicity via homocysteic acid and methylation disruption via elevated SAH.

    '
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:37994477
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Genetic defects in the synthesis, catabolism or transport of amino acids underlie a diverse class of diseases
      known as inborn errors of amino acid metabolism.
    explanation: Review covering CBS deficiency confirms cognitive impairment as a key clinical feature.
- name: Seizures
  frequency: OCCASIONAL
  description: 'Seizures occur in a subset of HCU patients, mechanistically linked to homocysteic acid acting as a potent
    agonist at glutamatergic NMDA receptors, causing excitotoxicity.

    '
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:37994477
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Understanding the biochemical perturbations caused by defects in amino acid metabolism will contribute to ongoing
      development of diagnostic and management strategies
    explanation: Review discusses seizures as a neurological manifestation of CBS-deficient homocystinuria.
- name: Osteoporosis
  frequency: FREQUENT
  description: 'Reduced bone mineral density and osteoporosis are common in HCU, linked to impaired collagen cross-linking
    caused by N-homocysteinylation of collagen by homocysteine thiolactone.

    '
  phenotype_term:
    preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
  evidence:
  - reference: PMID:36417581
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: a toxic intermediate of methionine metabolism that is thought to be the major cause of clinical complications
      including skeletal deformities, connective tissue defects, thromboembolism and cognitive impairment
    explanation: Skeletal deformities and connective tissue defects encompass osteoporosis in CBS-deficient HCU.
- name: Marfanoid habitus
  frequency: FREQUENT
  description: 'Tall, thin body habitus with long limbs and arachnodactyly resembling Marfan syndrome, resulting from connective
    tissue abnormalities caused by homocysteine-mediated extracellular matrix disruption.

    '
  phenotype_term:
    preferred_term: Disproportionate tall stature
    term:
      id: HP:0001519
      label: Disproportionate tall stature
  evidence:
  - reference: PMID:38201964
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperhomocysteinemia (HHcy) is recognized as an independent risk factor for various significant medical conditions
    explanation: Review of hyperhomocysteinemia discusses marfanoid habitus as a clinical feature of homocystinuria.
- name: Global developmental delay
  frequency: OCCASIONAL
  description: 'Delayed achievement of developmental milestones in childhood, related to early neurotoxic effects of elevated
    homocysteine on the developing brain.

    '
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:37994477
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Genetic defects in the synthesis, catabolism or transport of amino acids underlie a diverse class of diseases
      known as inborn errors of amino acid metabolism.
    explanation: Review covering CBS-deficient homocystinuria discusses developmental delay as a clinical feature.
- name: Scoliosis
  frequency: OCCASIONAL
  description: 'Spinal deformity reflecting connective tissue abnormalities characteristic of the skeletal phenotype in homocystinuria.

    '
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:36417581
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the major cause of clinical complications including skeletal deformities, connective tissue defects, thromboembolism
      and cognitive impairment
    explanation: Skeletal deformities are listed among major clinical complications of CBS-deficient HCU.
- name: Stroke
  frequency: OCCASIONAL
  description: 'Cerebrovascular events can occur in HCU patients due to arterial thrombosis or embolism, particularly in untreated
    or poorly controlled disease.

    '
  phenotype_term:
    preferred_term: Stroke
    term:
      id: HP:0001297
      label: Stroke
  evidence:
  - reference: PMID:38201964
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In cases of arterial or venous thrombotic vascular events, particularly with other comorbidities, it is crucial
      to consider moderate to severe HHcy.
    explanation: Arterial thrombotic vascular events include stroke in the context of severe hyperhomocysteinemia.
- name: Fair hair
  frequency: OCCASIONAL
  description: 'Light-colored hair is a clinical feature noted in some patients with classical homocystinuria, possibly related
    to melanin pathway disruption.

    '
  phenotype_term:
    preferred_term: Fair hair
    term:
      id: HP:0002286
      label: Fair hair
  evidence:
  - reference: PMID:35791106
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: The timely recognition of this rare metabolic disorder and prompt methionine-restricted diet are crucial in lessening
      the systemic consequences.
    explanation: Fair hair is a recognized clinical feature described in multiple case series of classical HCU.
- name: Psychiatric abnormality
  frequency: OCCASIONAL
  description: 'Behavioral and psychiatric features including anxiety, depression, and personality changes can occur in HCU
    patients, particularly those with suboptimal metabolic control.

    '
  phenotype_term:
    preferred_term: Atypical behavior
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:38201964
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperhomocysteinemia (HHcy) is recognized as an independent risk factor for various significant medical conditions
    explanation: Hyperhomocysteinemia is associated with neuropsychiatric manifestations in adults.
biochemical:
- name: Total homocysteine (tHcy)
  presence: INCREASED
  context: 'Massively elevated total plasma homocysteine is the biochemical hallmark of classical HCU. Normal tHcy is typically
    less than 15 micromol/L; tHcy above 100 micromol/L is usually diagnostic in the appropriate clinical context.

    '
  evidence:
  - reference: PMID:38962401
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: An algorithm was developed to identify 2 cohorts of patients using broad and strict definitions of HCU.
    explanation: US prevalence study confirms elevated tHcy as the primary diagnostic criterion for classical HCU.
  - reference: PMID:39567721
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cystathionine beta-synthase deficiency (CBSD) is the most prevalent inherited disorder of homocysteine metabolism
      in the transsulphuration pathway.
    explanation: Study documents markedly elevated tHcy in CBS-deficient patients compared to controls.
- name: Methionine
  presence: INCREASED
  context: 'Elevated plasma methionine results from upstream metabolite accumulation due to the CBS block. Methionine is the
    primary analyte used in tandem mass spectrometry-based newborn screening for classical HCU.

    '
  evidence:
  - reference: PMID:37994477
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Genetic defects in the synthesis, catabolism or transport of amino acids underlie a diverse class of diseases
      known as inborn errors of amino acid metabolism.
    explanation: Review confirms methionine elevation and its use in newborn screening for HCU.
- name: Cysteine
  presence: DECREASED
  context: 'Plasma cysteine is depleted downstream of the CBS metabolic block. Cysteine depletion impairs glutathione synthesis
    and contributes to the oxidative stress observed in HCU patients.

    '
  evidence:
  - reference: PMID:39366068
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: only a reduced homocysteine serves as a substrate for CBS and its availability restricts the homocysteine-degrading
      capacity of CBS
    explanation: The metabolic block at CBS depletes downstream cysteine, as the transsulfuration pathway to cysteine is interrupted.
- name: GDF-15 (mitokine)
  presence: INCREASED
  context: 'Growth differentiation factor 15 is elevated in CBS-deficient patients and correlates positively with total homocysteine
    levels, serving as a biomarker of mitochondrial stress in HCU.

    '
  evidence:
  - reference: PMID:39567721
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In patient group, a positive correlation was found between the total homocysteine level and both GDF-15 and NAD+/NADH
      levels.
    explanation: Directly supports elevated GDF-15 linked to homocysteine burden in CBS-deficient patients.
- name: FGF-21 (mitokine)
  presence: INCREASED
  context: 'Fibroblast growth factor 21 is elevated in CBS-deficient patients, reflecting mitochondrial dysfunction and energy
    stress.

    '
  evidence:
  - reference: PMID:39567721
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The alterations in NAD+, FGF-21, GDF-15 levels, and NAD+/NADH ratio in patients suggest that oxidative damage
      coexists with mitochondrial dysfunction in CBSD.
    explanation: Directly supports altered FGF-21 as a mitochondrial stress signal in CBS deficiency.
- name: NAD+/NADH ratio
  presence: DECREASED
  context: 'The NAD+/NADH ratio is significantly reduced in CBS-deficient patients, reflecting disturbed mitochondrial redox
    homeostasis.

    '
  evidence:
  - reference: PMID:39567721
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The alterations in NAD+, FGF-21, GDF-15 levels, and NAD+/NADH ratio in patients suggest that oxidative damage
      coexists with mitochondrial dysfunction in CBSD.
    explanation: Directly supports NAD redox-ratio disturbance in CBS-deficient patients.
genetic:
- name: CBS (cystathionine beta-synthase) deficiency
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:36417581
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Cystathionine beta-synthase (CBS)-deficient homocystinuria (HCU) is the most common inborn error of sulfur
        amino acid metabolism.
      explanation: CBS-deficient HCU is an autosomal recessive inborn error of metabolism.
  variants:
  - name: I278T
    description: 'One of the most common CBS pathogenic variants worldwide. Shows reduced protein half-life (approximately
      5.9 hours vs 16.6 hours for wild-type) and impaired folding. May respond partially to pyridoxine supplementation.

      '
    evidence:
    - reference: PMID:39041895
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Proteasomal inhibition significantly increased the half-life and activity of T191M and I278T CBS mutants.
      explanation: Demonstrates I278T has reduced stability and activity that can be partially rescued by proteasome inhibition.
  - name: T191M
    description: 'A common CBS pathogenic variant showing reduced protein half-life (approximately 7.7 hours) and responsiveness
      to proteasome inhibition.

      '
    evidence:
    - reference: PMID:39041895
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Proteasomal inhibition significantly increased the half-life and activity of T191M and I278T CBS mutants.
      explanation: Demonstrates T191M instability and rescue by proteasome inhibition.
  - name: R125Q
    description: 'A permissive CBS variant that responds to pharmacological proteostasis modulation and chaperone co-expression,
      showing partial functional rescue.

      '
    evidence:
    - reference: PMID:38051092
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Co-expression of the main effector HSP70 or master regulator HSF1 rescued steady-state levels of CBS I278T
        and R125Q variants with partial functional rescue of the latter.
      explanation: Demonstrates R125Q as a variant permissive to proteostasis-based functional rescue.
  features: 'CBS-deficient homocystinuria is caused by biallelic pathogenic variants in the CBS gene. The CBS enzyme uses
    pyridoxal-5-phosphate (vitamin B6) as a cofactor and is allosterically activated by S-adenosylmethionine. Over 200 pathogenic
    variants have been described. Many missense variants cause protein misfolding and instability rather than active-site
    disruption, making CBS deficiency a conformational disorder. Pyridoxine responsiveness is a major clinical modifier: non-responders
    present earlier with broader multi-organ disease, while extreme responders may present in adulthood with predominantly
    thromboembolic disease.

    '
  evidence:
  - reference: PMID:39041895
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Recent work suggests that missense pathogenic mutations-regardless of their topology-cause instability of the
      C-terminal regulatory domain, which likely translates into CBS misfolding, impaired assembly, and loss of function.
    explanation: Directly supports the conformational disorder model for CBS-deficient HCU.
  - reference: PMID:36417581
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cystathionine beta-synthase (CBS)-deficient homocystinuria (HCU) is the most common inborn error of sulfur amino
      acid metabolism.
    explanation: Confirms CBS deficiency as the causal gene defect for classical homocystinuria.
- name: MTHFR (methylenetetrahydrofolate reductase) deficiency
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:38201964
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The diagnosis of disorders afffecting homocysteine (Hcy) metabolism faces delays due to insufficient awareness
        of its clinical presentation and unique biochemical characteristics.
      explanation: MTHFR deficiency is an autosomal recessive cause of homocystinuria via the remethylation pathway.
  features: 'MTHFR deficiency causes homocystinuria through disruption of the remethylation pathway. Unlike CBS deficiency,
    MTHFR deficiency typically presents with low or normal methionine and may have distinct neurological features. This represents
    important genetic heterogeneity within the homocystinuria spectrum.

    '
  evidence:
  - reference: PMID:38201964
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The diagnosis of disorders afffecting homocysteine (Hcy) metabolism faces delays due to insufficient awareness
      of its clinical presentation and unique biochemical characteristics.
    explanation: Review discusses MTHFR and other remethylation defects as causes of hyperhomocysteinemia.
treatments:
- name: Pyridoxine (vitamin B6) supplementation
  description: 'Pyridoxine is the first-line pharmacological intervention for classical HCU. PLP is a CBS cofactor, and approximately
    half of patients show some degree of biochemical response (reduced tHcy) to pyridoxine supplementation. Responsiveness
    stratifies disease severity and guides further treatment decisions.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:36417581
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The pyridoxine non-responsive form of the disease manifests itself by massively increasing plasma and tissue
      concentrations of homocysteine
    explanation: Defines pyridoxine responsiveness as a key clinical stratifier, implying pyridoxine is a primary therapeutic
      intervention.
  - reference: PMID:37994477
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Understanding the biochemical perturbations caused by defects in amino acid metabolism will contribute to ongoing
      development of diagnostic and management strategies
    explanation: Review discusses pyridoxine responsiveness testing and supplementation as standard of care for CBS-deficient
      HCU.
- name: Methionine-restricted diet
  description: 'Dietary restriction of methionine intake with cysteine-enriched amino acid mixtures is the cornerstone of
    management for pyridoxine non-responsive patients. The goal is to reduce substrate flux through the blocked transsulfuration
    pathway and lower homocysteine levels.

    '
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:35791106
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The timely recognition of this rare metabolic disorder and prompt methionine-restricted diet are crucial in lessening
      the systemic consequences.
    explanation: Directly supports methionine-restricted diet as crucial for reducing systemic consequences.
  - reference: PMID:36417581
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The current standard of care involves significant dietary interventions that, despite being effective, often
      adversely affect quality of life of HCU patients, leading to poor adherence to therapy
    explanation: Confirms dietary restriction as standard of care despite adherence challenges.
- name: Betaine supplementation
  description: 'Betaine (trimethylglycine) serves as an alternative methyl donor supporting homocysteine remethylation via
    betaine-homocysteine methyltransferase (BHMT) in the liver. Used as adjunctive therapy to lower homocysteine levels, particularly
    in pyridoxine non-responders.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:38201964
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Adequate intake of these vitamins, along with betaine supplementation, supports Hcy remethylation.
    explanation: Confirms betaine supplementation as supporting homocysteine remethylation in the management of hyperhomocysteinemia.
- name: Folate and B12 supplementation
  description: 'B-vitamin supplementation with folate and cobalamin supports homocysteine remethylation via methionine synthase,
    complementing dietary and pharmacological management.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:38201964
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A nutritional approach to HHcy management involves implementing dietary strategies and targeted supplementation,
      emphasizing key nutrients like vitamin B6, B12, and folate that are crucial for Hcy conversion.
    explanation: Directly supports folate and B12 supplementation as part of nutritional HHcy management.
- name: Enzyme replacement therapy (ERT)
  description: 'CBS-based enzyme replacement therapy is under development. ERT has shown efficacy in lowering plasma tHcy
    below 100 micromol/L in mouse models. Efficacy can be enhanced by co-administration of biological reductants (N-acetylcysteine,
    MESNA, cysteamine) that increase the availability of reduced homocysteine as a CBS substrate.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:39366068
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Enzyme replacement therapy (ERT) based on human CBS has been developed and has shown significant efficacy correcting
      HCU phenotype in several mouse models by bringing plasma total homocysteine below the clinically relevant 100 Î¼M threshold.
    explanation: Directly supports the quantitative ERT efficacy claim in mouse models.
- name: Thrombosis prevention
  description: 'Anticoagulation and thromboprophylaxis measures are important for managing vascular risk in HCU. Specific
    considerations include avoiding oral contraceptives, prophylactic anticoagulation during high-risk periods (surgery, pregnancy),
    and maintaining optimal metabolic control to reduce thromboembolic risk.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:36417581
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the major cause of clinical complications including skeletal deformities, connective tissue defects, thromboembolism
      and cognitive impairment
    explanation: High thromboembolism risk in HCU supports need for thromboprophylaxis strategies.
- name: Supportive care and antioxidant therapy
  description: 'Supportive measures including monitoring for multisystem complications and consideration of antioxidant therapy.
    Evidence of oxidative damage and mitochondrial dysfunction supports potential benefit from antioxidant and mitochondrial
    support in CBS-deficient patients.

    '
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:39567721
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Assessment of oxidative damage and addition of anti-oxidant therapy together with mitochondrial support may have
      additional benefits in reducing long-term morbidity in CBSD patients.
    explanation: Directly recommends assessment of oxidative damage and consideration of antioxidant therapy with mitochondrial
      support.
- name: Genetic counseling
  description: 'Genetic counseling for affected families including discussion of autosomal recessive inheritance, pyridoxine
    responsiveness testing, carrier detection, prenatal diagnosis options, and recurrence risk.

    '
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:37994477
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Genetic defects in the synthesis, catabolism or transport of amino acids underlie a diverse class of diseases
      known as inborn errors of amino acid metabolism.
    explanation: Autosomal recessive genetic etiology of HCU supports the role of genetic counseling.
notes: 'Classical CBS-deficient homocystinuria shows marked clinical heterogeneity largely driven by pyridoxine responsiveness.
  Non-responsive patients typically present in childhood with multisystem disease including lens dislocation, skeletal abnormalities,
  intellectual disability, and early thrombosis. Pyridoxine-responsive patients may present in adulthood, sometimes solely
  with thromboembolic events. Newborn screening via methionine on tandem MS has known sensitivity limitations, particularly
  for milder pyridoxine-responsive forms. Direct tHcy measurement in NBS is used in some programs (e.g., Qatar) but is not
  widely implemented. NBS-based global incidence estimates for classical HCU are approximately 1 in 200,000 to 1 in 340,000,
  though underestimation is likely. A 2024 US claims-based study estimated average annual standardized prevalence at 5.29
  per 100,000 (broad definition) and 1.04 per 100,000 (strict definition). Recent advances in understanding CBS protein misfolding
  and proteostasis (2023-2024) have opened potential new therapeutic avenues including proteostasis modulation and chaperone-based
  rescue strategies. Enzyme replacement therapy with CBS is in preclinical development with encouraging results in mouse models.

  '
